Wall Street analyst estimates for Climb Bio, Inc. (CLYM): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.19 | ||
| 2026-08-06 | $-0.18 | $-0.21 | +14.0% |
| 2026-05-07 | $-0.20 | $-0.26 | +23.1% |
| 2026-03-05 | $-0.26 | $-0.20 | -30.0% |
| 2025-11-06 | $-0.19 | $-0.16 | -18.8% |
| 2025-08-12 | $-0.13 | $-0.19 | +31.6% |
| 2025-05-14 | $-0.31 | $-0.15 | -106.7% |
| 2025-03-25 | $-0.13 | $-0.15 | +13.3% |
Valuation Ratios
| Price / Book | 4.49 |
| EV / EBITDA | -14.25 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | $97000 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | -$97000 |
| Research & Development | $4.0M | $9.3M | $23.3M | $26.2M | $15.4M | $14.3M | $46.6M |
| Selling, General & Admin | $677000 | $2.4M | $12.3M | $18.9M | $24.9M | $16.0M | $21.2M |
| Operating Expenses | $7.4M | $20.9M | $35.7M | $45.1M | $40.3M | $82.0M | $67.8M |
| Operating Income | -$7.4M | -$20.9M | -$35.7M | -$45.1M | -$40.3M | -$82.0M | -$67.9M |
| EBITDA | -$4.7M | -$11.8M | -$47.5M | -$45.2M | -$35.1M | -$30.4M | -$59.8M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$6.5M | -$20.7M | -$47.5M | -$45.2M | -$35.1M | -$73.9M | -$59.9M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$6.5M | -$20.7M | -$47.5M | -$45.2M | -$35.1M | -$73.9M | -$59.9M |
| EPS | $-0.56 | $-1.97 | $-4.24 | $-1.72 | $-1.30 | $-1.53 | $-0.88 |
| EPS (Diluted) | $-0.56 | $-1.97 | $-4.24 | $-1.72 | $-1.30 | $-1.53 | $-0.88 |
| Shares Outstanding (Diluted) | $11.7M | $11.7M | $12.3M | $26.3M | $27.0M | $48.2M | $67.8M |
Price
| Price | $14.11 |
| Market Cap | $808M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABOS · ACTU · AGEN · ANIX · ENTX · INO · MCRB
Explore sector: Healthcare · Biotechnology
More sections of CLYM: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks